Screening of Preferential Binding Affinity of Selected Natural Compounds to SARS-CoV-2 Proteins Using in Silico Methods
Objectives: The global burden of the current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing the corona virus disease-19 (COVID-19) is enormous. No definitive treatment and prophylactic guidelines for COVID-19 currently exist except for physical distancing and aerial barriers between individuals. This work explored the natural compound-binding efficiency of SARS-CoV-2 proteins essential for host cell interaction and infection.
Methods: The binding activity of artemisinin to SARS-CoV-2 spike glycoprotein (Protein Data Bank (PDB) ID: 6VYB), SARS-CoV-2 main protease (3C-like main protease (3CLpro); PDB ID: 6Y84) and SARS-CoV-2 papain-like protease (PLpro; PDB ID: 6W9C), were tested using in silico methods. Moreover, chloroquine and hesperidin were used as the positive control of binding affinity and proven therapeutic effect, respectively.
Results: The highest affinities for binding to all tested SARS-CoV-2 proteins are observed for hesperidin (−5.8,−10.0, and −8.1 kcal/mol), then for artemisinin (−4.8,−8.3, and −6.0 kcal/mol), and the lowest for chloroquine (−4.1,−8.2, and −4.8 kcal/mol). Artemisinin, hesperidin, and chloroquine had similar positioning toward targeted proteins at specific sites when these interactions were visualized.
Conclusion: This study shows that artemisinin has the potential to bind and inhibit the SARS-CoV-2 spike protein, the 3CLpro main protease, and PLpro proteinase similar to hesperidin and chloroquine that have been proven as antivirals in previous preclinical and clinical studies.
1.Eckhardt M, Hultquist J, Kaake R, Hüttenhain R, Krogan N. A systems approach to infectious disease. Nat Rev Genet 2020;21:339–54.
2. Zhou Y, Hou Y, Shen J, Huang Y, Martin W, Cheng F. Networkbased drug repurposing for novel coronavirus 2019-nCoV/ SARS-CoV-2. Cell Discov2020;6:14.
3. Li Z, Wang X, Cao D, Sun R, Li C, Li G. Rapid review for the anti-coronavirus effect of remdesivir. Drug DiscovTher2020;14:73–6.
4. Ang L, Lee H, Choi J, Zhang J, Lee M. Herbal medicine and pattern identification for treating COVID-19: a rapid review of guidelines. Integr Med Res 2020;9:100407.
5. Hall D, Ji H. A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease. Travel Med Infect Dis 2020;35:101646.
6. Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B 2020;10:766–88.
7. Chen Y, Yiu C, Wong K. Prediction of the SARS-CoV-2 (2019- nCoV) 3C-like protease (3CLpro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates. F1000Res 2020;9:129.
8. Adem S, Eyupoglu V, Sarfraz I, Rasul A, Ali M. Identification of Potent COVID-19 Main Protease (Mpro) Inhibitors from Natural Polyphenols: An in Silico Strategy Unveils a Hope against CORONA. Preprints. 2020 Mar 23. doi: 10.20944/preprints202003.0333.v1. [Epub ahead of print].
9. Utomo R, Ikawati M, Meiyanto E. Revealing the Potency of Citrus and Galangal Constituents to Halt SARS-CoV-2 Infection. Preprints. 2020 Mar 12.doi: 10.20944/preprints202003.0214. v1. [Epub ahead of print].
10. Das S, Sarmah S, Lyndem S, Singha Roy A. An investigation into the identification of potential inhibitors of SARS-CoV-2 main protease using molecular docking study. J Biomol Struct Dyn. 2020 May 13. doi: 10.1080/07391102.2020.1763201. [Epub ahead of print].
11. Joshi RS, Jagdale SS, Bansode SB, Shankar SS, Tellis MB, Pandya VK, et al. Discovery of potential multi-target-directed ligands by targeting host-specific SARS-CoV-2 structurally conserved main protease. J Biomol Struct Dyn. 2020 May 5. doi: 10.1080/07391102.2020.1760137. [Epub ahead of print].
12. Bellavite P, Donzelli A. Hesperidin and SARS-CoV-2: New Light on the Healthy Function of Citrus Fruits. Antioxidants 2020;9:742.
13. Cheke R. The Molecular Docking Study of Potential Drug Candidates Showing Anti-COVID-19 Activity by Exploring of Therapeutic Targets of SARS-CoV-2. Eurasian J Med Oncol 2020;4:185–95.
14. Klayman D. Qinghaosu (artemisinin): an antimalarial drug from China. Science 1985;228:1049–55.
15. Tu Y. The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine. Nat Med 2011;17:1217–20.
16. Vidic D, Čopra-Janićijević A, Miloš M, Maksimović M. Effects of Different Methods of Isolation on Volatile Composition of Artemisia annua L. Int J Anal Chem 2018;2018:1–6.
17. WHO.Guidelines for the treatment of malaria. Geneva: WHO; 2006.
18. Gendrot M, Duflot I, Boxberger M, Delandre O, Jardot P, Le Bideau M, et al. Antimalarial artemisinin-based combination therapies (ACT) and COVID-19 in Africa: In vitro inhibition of SARS-CoV-2 replication by mefloquine-artesunate. Int J Infect Dis 2020;99:437–40.
19. Haq FU, Roman M, Ahmad K, Rahman SU, Shah SMA, Suleman N, et al. Artemisia annua: Trials are needed for COVID-19. Phytother Res 2020;34:2423–24.
20. de CosséBrissac C, Nordmann L, Rollin M, Sattler M, Saison N. Call for proposal for fighting against COVID-19 : prevent and mitigate the epidemic with the Artemisia annua. Maison de l’Artemisia 2020. Available at: https://inter-culturel.net/IMG/pdf/artemisia_ appeal_english_version.pdf. Accessed Dec 7, 2020.
21. Peplow M. Artemisinin raises hopes and fears amid COVID-19. Chem Eng News 2020;98:26–7.
22. Trott O, Olson, A. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. JComput Chem2010;31:455–61.
23. Umesh, Kundu D, Selvaraj C, Singh SK, Dubey VK. Identification of new anti-nCoV drug chemical compounds from Indian spices exploiting SARS-CoV-2 main protease as target. J Biomol Struct Dyn. 2020 May 2. doi: 10.1080/07391102.2020.1763202. [Epub ahead of print].
24. Maiti BK. Can Papain-like Protease Inhibitors Halt SARS-CoV-2 Replication? ACS Pharmacol Transl Sci 2020;3:1017–9.
25. Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 2020;581:215–20.
26. Wang Q, Zhang Y, Wu L, Niu S, Song C, Zhang Z, et al. Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2. Cell 2020;181:894–904.e9
27. Kalathiya U, Padariya M, Mayordomo M, Lisowska M, Nicholson J, Singh A, et al. Highly Conserved Homotrimer Cavity Formed by the SARS-CoV-2 Spike Glycoprotein: A Novel Binding Site. J Clin Med 2020;9:1473.
28. Shah M, Ahmad B, Choi S, Woo H. Sequence variation of SARSCoV-2 spike protein may facilitate stronger interaction with ACE2 promoting high infectivity. Preprint Research Square. 2020 Mar 17. doi: 10.21203/rs.3.rs-16932/v1. [Epub ahead of print].
29. DeLano W. Pymol: an open-source molecular graphics tool. CCP4 Newsletter On Protein Crystallography 2002,40:82–92.
30. Xia S, Liu Q, Wang Q, Sun Z, Su S, Du L, et al. Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein. Virus Res 2014;194:200–10.
31. Sharma S, Deep S. In-silico drug repurposing for targeting SARS-CoV-2 Mpro. ChemRxiv. 2020
32. Samant L, Javle V. Comparative Docking analysis of rational drugs against COVID-19 Main Protease. ChemRxiv. 2020 Apr 9. doi: https://doi.org/10.26434/chemrxiv.12210845.v1. [Epub ahead of print].
33. Eccles R, Meier C, Jawad M, Weinmüllner R, Grassauer A, Prieschl-Grassauer E. Efficacy and safety of an antiviral IotaCarrageenan nasal spray: a randomized, double-blind, placebo-controlled exploratory study in volunteers with early symptoms of the common cold. Respir Res 2010;11:108.
34. Wilhelmus KR. Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis. Cochrane Database Syst Rev 2015;1:CD002898.